{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:42:13Z","timestamp":1790221333385,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1002\/jcph.792","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T07:23:48Z","timestamp":1468308228000},"page":"173-184","source":"Crossref","is-referenced-by-count":60,"title":["Physiologically Based Pharmacokinetic Modeling of Palbociclib"],"prefix":"10.1002","volume":"57","author":[{"given":"Yanke","family":"Yu","sequence":"first","affiliation":[{"name":"Clinical Pharmacology; Global Product Development; Pfizer; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Ming","family":"Loi","sequence":"additional","affiliation":[{"name":"Pharmacokinetics; Dynamics and Metabolism; Pfizer Worldwide Research and Development; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Global Product Development; Pfizer; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Global Product Development; Pfizer; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"issue":"11","key":"10.1002\/jcph.792-BIB0001|jcph792-cit-0001","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"10.1002\/jcph.792-BIB0002|jcph792-cit-0002","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Research: BCR"},{"issue":"1","key":"10.1002\/jcph.792-BIB0003|jcph792-cit-0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"21","key":"10.1002\/jcph.792-BIB0004|jcph792-cit-0004","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1002\/jcph.792-BIB0005|jcph792-cit-0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","article-title":"Palbociclib: first global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"10.1002\/jcph.792-BIB0006|jcph792-cit-0006","unstructured":"Pfizer Inc Ibrance\u00ae (palbociclib): US prescribing information 2015 http:\/\/www.accessdata.fda.gov"},{"issue":"2","key":"10.1002\/jcph.792-BIB0007|jcph792-cit-0007","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1002\/jcph.792-BIB0008|jcph792-cit-0008","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2\/1)","volume":"104","author":"Schwartz","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"15 Suppl","key":"10.1002\/jcph.792-BIB0009|jcph792-cit-0009","article-title":"A phase 1 randomized, open-label, fixed-sequence, 2-period study of the effect of multiple doses of rifampin on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers [Abstract 4515]","volume":"75","author":"Hoffman","year":"2015","journal-title":"Cancer Research"},{"key":"10.1002\/jcph.792-BIB0010|jcph792-cit-0010","article-title":"A phase 1 open-label fixed-sequence two-period crossover study of the effect of multiple doses of itraconazole on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers [Abstract LB-198]. AACR Annual Meeting","volume":"76","author":"Hoffman","year":"2016","journal-title":"Cancer Res."},{"issue":"19 suppl","key":"10.1002\/jcph.792-BIB0011|jcph792-cit-0011","article-title":"A phase 1 randomized, open-label, 2-sequence, 2-period crossover study of the effect of multiple doses of palbociclib (PD-0332991) on midazolam pharmacokinetics in healthy women of non-childbearing potential [Abstract CT-419]","volume":"74","author":"Hoffman","year":"2014","journal-title":"Cancer Res."},{"issue":"10","key":"10.1002\/jcph.792-BIB0012|jcph792-cit-0012","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1124\/dmd.115.064618","article-title":"Prediction of drug-drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model","volume":"43","author":"Yamazaki","year":"2015","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"10.1002\/jcph.792-BIB0013|jcph792-cit-0013","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","article-title":"Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review","volume":"89","author":"Zhao","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/jcph.792-BIB0014|jcph792-cit-0014","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"In silico\u201d simulations to assess the \u201cin vivo\u201d consequences of \u201cin vitro\u201d metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discovery Today Technologies"},{"issue":"3","key":"10.1002\/jcph.792-BIB0015|jcph792-cit-0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"issue":"9","key":"10.1002\/jcph.792-BIB0016|jcph792-cit-0016","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/bdd.1919","article-title":"Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation","volume":"35","author":"Lu","year":"2014","journal-title":"Biopharmaceutics & Drug Disposition"},{"issue":"3","key":"10.1002\/jcph.792-BIB0017|jcph792-cit-0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-013-0117-y","article-title":"Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations","volume":"53","author":"Hsu","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1002\/jcph.792-BIB0018|jcph792-cit-0018","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.114.062596","article-title":"Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics","volume":"43","author":"Djebli","year":"2015","journal-title":"Drug Metabolism and Disposition"},{"issue":"6","key":"10.1002\/jcph.792-BIB0019|jcph792-cit-0019","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00228-012-1467-3","article-title":"Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure","volume":"69","author":"Yeo","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/jcph.792-BIB0020|jcph792-cit-0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bcp.12588","article-title":"Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity","volume":"80","author":"Ogungbenro","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/jcph.792-BIB0021|jcph792-cit-0021","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/bcp.12743","article-title":"The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetics model","volume":"80","author":"Emoto","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/jcph.792-BIB0022|jcph792-cit-0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1208\/s12248-009-9107-2","article-title":"Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data","volume":"11","author":"Lukacova","year":"2009","journal-title":"The AAPS Journal"},{"issue":"1","key":"10.1002\/jcph.792-BIB0023|jcph792-cit-0023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.2012.64","article-title":"Physiologically based pharmacokinetic (PBPK) modeling in children","volume":"92","author":"Barrett","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/jcph.792-BIB0024|jcph792-cit-0024","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clinical Pharmacokinetics"},{"issue":"19 suppl","key":"10.1002\/jcph.792-BIB0025|jcph792-cit-0025","article-title":"A phase 1, single-dose, fixed-sequence, 2-period crossover absolute oral bioavailability study in healthy volunteers comparing oral to intravenous administration of palbociclib (PD-0332991) [Abstract M1-323]. AAPS Annual Meeting","volume":"74","author":"Hoffman","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1002\/jcph.792-BIB0026|jcph792-cit-0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/jcph.792-BIB0027|jcph792-cit-0027","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"10.1002\/jcph.792-BIB0028|jcph792-cit-0028","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jps.20323","article-title":"Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat","volume":"94","author":"Rodgers","year":"2005","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"10.1002\/jcph.792-BIB0029|jcph792-cit-0029","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"5","key":"10.1002\/jcph.792-BIB0030|jcph792-cit-0030","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharmaceutical Research"},{"issue":"2","key":"10.1002\/jcph.792-BIB0031|jcph792-cit-0031","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1002\/jcph.792-BIB0032|jcph792-cit-0032","article-title":"A phase one open-label single-radiolabeled dose study to investigate the absorption, metabolism, and excretion of [14C]PD-0332991 in healthy male volunteers","author":"Loi","year":"2014","journal-title":"ISSX Annual Meeting"},{"issue":"4","key":"10.1002\/jcph.792-BIB0033|jcph792-cit-0033","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.2010.03883.x","article-title":"In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype","volume":"71","author":"Rekic","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/jcph.792-BIB0034|jcph792-cit-0034","unstructured":"US FDA Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations 2012"},{"key":"10.1002\/jcph.792-BIB0035|jcph792-cit-0035","unstructured":"European Medicine Agency Guideline on the Investigation of Drug Interactions. 2012"},{"issue":"1","key":"10.1002\/jcph.792-BIB0036|jcph792-cit-0036","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40262-014-0188-4","article-title":"Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration","volume":"54","author":"Wagner","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"issue":"4","key":"10.1002\/jcph.792-BIB0037|jcph792-cit-0037","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-015-0330-y","article-title":"Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA","volume":"55","author":"Wagner","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"issue":"3","key":"10.1002\/jcph.792-BIB0038|jcph792-cit-0038","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1002\/jcph.792-BIB0039|jcph792-cit-0039","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.109.026658","article-title":"Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metabolism and Disposition"},{"issue":"5","key":"10.1002\/jcph.792-BIB0040|jcph792-cit-0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Current Drug Metabolism"},{"issue":"4","key":"10.1002\/jcph.792-BIB0041|jcph792-cit-0041","first-page":"226","article-title":"Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"7","key":"10.1002\/jcph.792-BIB0042|jcph792-cit-0042","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"issue":"11","key":"10.1002\/jcph.792-BIB0043|jcph792-cit-0043","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1177\/0091270010387141","article-title":"Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?","volume":"51","author":"Friedman","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/jcph.792-BIB0044|jcph792-cit-0044","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1002\/jcph.792-BIB0045|jcph792-cit-0045","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/dmd.115.065326","article-title":"Determination of a degradation constant for CYP3A4 by direct suppression of mRNA in a novel human hepatocyte model, HepatoPac","volume":"43","author":"Ramsden","year":"2015","journal-title":"Drug Metabolism and Disposition"},{"issue":"9","key":"10.1002\/jcph.792-BIB0046|jcph792-cit-0046","doi-asserted-by":"crossref","first-page":"e70330","DOI":"10.1371\/journal.pone.0070330","article-title":"Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data","volume":"8","author":"Yamashita","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1002\/jcph.792-BIB0047|jcph792-cit-0047","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/jpet.107.124610","article-title":"Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor","volume":"323","author":"Fang","year":"2007","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.792","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:46Z","timestamp":1657803826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.792"}},"subtitle":["PBPK Modeling of Palbociclib"],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.792","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}